

± 44.4 MBq. PET images were acquired on an integrated PET/CT camera system (Biograph mCT 40 slice, Siemens Medical Solution, IL, USA). Whole-body scan from mid-thigh to the vertex of the skull was acquired with 3 minutes per bed position at one hour after injection of ¹⁸F-FDG. Diagnostic contrast-enhanced CT was performed adjusted for the patient's weight: tube voltage of 120 kV, tube –current product 40–150 mAs with an online tube current modulation section width of 5 mm and pitch factor of 0.8. CT images were enhanced with 100 ml of intravenous non-ionic contrast (GE Healthcare WI, USA). CT images were used for attenuation correction and anatomic localization.

⁶⁸Ga-citrate preparation

⁶⁸Ga-citrate was prepared using compounded radio labeling of ⁶⁸Ga-citrate with radioactivity eluted from a SnO₂-based ⁶⁸Ge/⁶⁸Ga-generator (iThemba LABS, Somerset West, South Africa) [15]. Briefly, ⁶⁸GaCl₃ yielded in 1–2 mL by eluate fractionation in 10 ml of 0.6 N hydrochloric acid, was added to directly to a vial containing anticoagulant citrate dextrose solution, USP formula A (ACD-A) in a one-step-aseptic procedure, incubated for 15–20 minutes with frequent vortexing. This method was based on a combination of the two previous protocols [13, 16]. All solvents used were of a pharmacological grade. Quality control was performed before ⁶⁸Ga-citrate injection, including instant thin-layer chromatography and determination of the pH value.

⁶⁸Ga-citrate PET/CT imaging

Patients were not required to fast before the study. Patients were injected with a mean activity of 140.2 ± 41.1 MBq of ⁶⁸Ga-citrate and mid-thigh to the vertex of skull images were acquired on the same PET/CT system used for the ¹⁸F-FDG studies. The mean circulating time after injection of the ⁶⁸Ga-citrate was 64.95 ± 5.3 minutes. The acquisition was 4 minutes per bed position, and a low dose non-contrasted CT was used for attenuation correction (tube voltage of 120 kV, tube –current product 40–50 mAs with a pitch factor of 1.5).

Image reconstruction and interpretation

PET images were reconstructed with and without CT based attenuation correction using ordered-subset expectation maximum and displayed as axial, sagittal, and coronal slices. Two nuclear physicians (AA and IL) who were aware of the patient's diagnosis of TB and their HIV status were asked to assess both the ¹⁸F-FDG and ⁶⁸Ga-citrate for sites of abnormal uptake. Sites of abnormal tracer uptake were noted, and we recorded lesions showing uptake of one tracer but not the other. Any differences were resolved by a third nuclear physician (MM) and correlated with anatomical data that had been reported by a board-certified radiologist.

PET analysis

After determining the sites of abnormal tracer uptake, AO drew the volume of interest (VOI) for each lesion. The SUVmax for each any abnormal lesion detected by either of the tracers was recorded. In patients with follow-up scans, the baseline study was compared to the follow-up study for ¹⁸F-FDG and ⁶⁸Ga-citrate. We calculated and compared the mean change in SUVmax of the lesion to the liver ratio from baseline to follow up for the two tracers.

► **Tab. 1** Patient demographic data and HIV parameters.

Patients (n)	18
Sex (female, n)	11 (61.1%)
Age (years, mean)	35.67 ± 13.53
HIV patients (n)	13 (72.2%)
CD4 count (median)	198 (32–1,008)
Viral load (median)	66 (0–232,916)

► **Tab. 2** Interval between ¹⁸F-FDG and ⁶⁸Ga-citrate studies.

Interval between scan pairs in days	Number of scan pairs	Percentage of scan pairs (%)	Cumulative percentage (%)
1	2	9	9
2	4	17	26
4	6	26	52
5	5	22	74
6	3	13	87
8	2	9	96
12	1	4	100

Statistical analysis

We used SPSS Version 23 for the statistical analysis. We used descriptive statistic to describe parameters such as the age, duration of treatment, and SUVmax of lesions. We used the Chi-squared test to determine the significance of the difference in the number of lesions detected by each tracer. The paired Students *t*-test was used to determine the significance of the difference in means SUV of the two tracers; the Cohen Kappa test was used to assess the agreement between ¹⁸F-FDG and ⁶⁸Ga-citrate PET/CT in the detection of lesions and follow-up in TB patients. The Pearson correlation coefficient was used to determine the association between the SUVmax of lesions detected by both ¹⁸F-FDG and ⁶⁸Ga-citrate.

Results

Finally, 18 patients received 46 PET/CT scans, 23 pairs of PET/CT studies: 23 ¹⁸F-FDG, and 23 ⁶⁸Ga-citrate PET/CT studies. The mean age of the patients was 35.7 ± 13.5 years, and 7 (39%) were males. The patient demographics and HIV parameters are summarized in ► **Table 1**.

Duration of anti-TB treatment before the scan and interval between scans

Six scan pairs were done within one week of initiation of anti-TB therapy; seven were done at two weeks, five scans were done at eight weeks, one pair each was done at nine weeks, ten weeks, 26 weeks, 39 weeks and 52 weeks after starting anti-TB therapy. The interval between the ¹⁸F-FDG and ⁶⁸Ga-citrate PET/CT studies for each scan pair has been tabulated in ► **Table 2** below.

► **Tab. 3** Diagnosis of TB.

Microscopically confirmed (n)	12 (66.7%)
Biopsy and culture (n)	3
Sputum polymerase chain reaction only	4
Sputum polymerase chain reaction and subsequent growth by culture	4
Sputum culture only	1
Clinical and follow up as per WHO algorithm for EPTB and SNTB (n)	6 (33.3%)
Extra-pulmonary tuberculosis only	1
Smear-negative tuberculosis	5

► **Tab. 4** Sites of abnormal lesions detected by ¹⁸F-FDG and ⁶⁸Ga-citrate.

Site	Number of patients (%)
Lungs ¹	12 (67)
Lymph nodes ^{1*}	13 (72)
Pleura ¹	2 (11)
Skin ¹	1 (5)
Liver ^{1*}	1 (5)
Spleen ¹	1 (5)
Joint ¹	1 (5)
Subcutaneous tissue ¹	1 (5)
Vertebrae and disc ^{2±}	1 (5)
Pericardium ²	1 (5)
Brain ^{1#}	1 (5)

¹ Lesions detected by both ¹⁸F-FDG and ⁶⁸Ga-citrate

² Lesions detected by ¹⁸F-FDG only

* Lower number lesions on ⁶⁸Ga-citrate

± Low uptake of ¹⁸F-FDG in assessment of residual TB

More clearly defined on ⁶⁸Ga-citrate

Diagnosis of TB and HIV co-infection

Twelve (67%) patients had their TB diagnosis confirmed by biopsy and culture or polymerase chain reaction (PCR) of the sputum. In six patients (33%), the diagnosis was per the WHO algorithm and National guidelines for the diagnosis and follow-up of SNTB and EPTB in an HIV-prevalent setting [2, 4]. ► **Table 3** shows how the diagnosis of TB was established. Thirteen patients (72%) were co-infected with HIV. The median CD4 count and viral load of TB/HIV patients were 198 (range 32–1,008) and 66 (range 0–232,918), respectively.

Lesions

In total, we counted 269 different lesions from both tracers. ¹⁸F-FDG detected 269 (97%) and ⁶⁸Ga-citrate detected 166 (62%) lesions, $p < 0.0001$. We found pulmonary involvement in 12 patients (67%), nodal involvement in 13 (72%), and pleural involvement in 3 (17%) of the patients. Other sites of abnormal tracer uptake included the

► **Tab. 5** Head-to-head comparison of ¹⁸F-FDG- and ⁶⁸Ga-citrate-PET/CT findings.

Abnormal uptake	N (%)	Comment
Concordance of all lesions	5 (27.7)	Four out of five cases were in HIV-negative patients.
More lesions on [¹⁸ F]FDG	11 (61.1)	Includes one patient who had TB-pericarditis, which was only visualized on ¹⁸ F-FDG-PET/CT. Most of the other lesions were lymph nodes.
Better defined on ⁶⁸ Ga-citrate	1 (5.6)	Both tracers detected larger brain abscesses. Smaller ones were only detected by ⁶⁸ Ga-citrate
Suspected residual disease	1 (5.6)	After one year of anti-TB, there was an equivocal uptake on the ¹⁸ F-FDG with no uptake on ⁶⁸ Ga-citrate. No further anti-TB was administered and clinical follow-up and an MRI 3 months later confirmed no residual TB
Concordant – all lesions detected by ¹⁸ F-FDG were also detected by ⁶⁸ Ga-citrate		


brain, spleen, liver, vertebrae and disc, skin, subcutaneous tissue, and joints (► **Table 4**) The mean SUVmax of the lesions detected was higher for ¹⁸F-FDG (5.73 ± 3.05) than the SUVmax for ⁶⁸Ga-citrate (3.01 ± 1.31) $p < 0.0001$.

Comparison of ¹⁸F-FDG and ⁶⁸Ga-citrate PET/CT findings in patients

We present the findings of the head-to-head tracer comparison in ► **Table 5**. We also depict the correlation of the SUVmax of ⁶⁸Ga-citrate and ¹⁸F-FDG in lesions in ► **Fig. 1**. There was a significant correlation between the SUVmax of the lesions that were detected by both ¹⁸F-FDG and ⁶⁸Ga-citrate. We noted complete concordance of all abnormal lesions in five patients (27.7%). Eleven patients (55.6%) had more lesions detected on ¹⁸F-FDG-PET/CT. The lesions that were seen on ¹⁸F-FDG and not on ⁶⁸Ga-citrate were usually located near the mediastinum and large vessels where the blood pool from ⁶⁸Ga-citrate made it difficult to discriminate the pathological uptake from the background. Furthermore, pericarditis was identified on ¹⁸F-FDG but could not on the ⁶⁸Ga-citrate due to the uptake of ⁶⁸Ga-citrate the cardiac blood pool.

Conversely, in one patient, ⁶⁸Ga-citrate showed better lesion definition of intracerebral lesions with better lesion-to-background ratio compared to the ¹⁸F-FDG studies with its inherently high level of background activity in the brain. The intracerebral lesions were better visualized on the ⁶⁸Ga-citrate study (► **Fig. 2**). In the last patient, there was ¹⁸F-FDG uptake but not ⁶⁸Ga-citrate in a patient who had completed anti-TB treatment and was for assessment of residual disease in the spine.

Using Cohen kappa analysis for the detection of abnormal tracer uptake in TB patients, we found substantial agreement between the two tracers in detection abnormal lesions in patients with TB (kappa 0.64).



► **Fig. 1** Correlation of SUVmax of lesions detected by both tracer

was unable to exclude residual disease in TB spondylodiscitis in a patient where ⁶⁸Ga-citrate was negative, in a patient who was determined to have no residual TB by clinical follow-up after a year of PET/CT scan with no anti-TB therapy. Also, ⁶⁸Ga-citrate did not accumulate in an inflammatory lesion due to healed post-staphylococcal abscess in a patient who had histologically confirmed TB arthritis of the right knee (► **Fig. 3**).

Follow-up

All our patients received first-line anti-TB drugs for the treatment of TB. We repeated the scans in five patients, all of whom had baseline studies. Four patients had their scans repeated after eight weeks of first-line anti-TB therapy and one patient after twenty-six week of first-line anti-TB therapy. In all five patients, both tracers showed a decreasing mean lesion to liver SUVmax ratio by both tracers in response to the anti-TB treatment (► **Table 6**). In all five patients, the decreasing lesion to liver ratio of SUVmax of both tracers with anti-TB treatment was consistent with the clinical outcome of the patients as indicated by their clinicians (measured by patient symptoms, weight, hemoglobin concentration changes, CRP and ESR). The percentage change for the mean lesion to liver SUVmax of the lesions in patients that had follow-up studies ranged from –95.2% to –33.6% for ¹⁸F-FDG while that of ⁶⁸Ga-citrate ranged from –85% to –43.1% (► **Table 6**).

Discussion

In this first head-to-head comparison of ¹⁸F-FDG and ⁶⁸Ga-citrate PET/CT in patients with TB, we found more abnormal lesions were detected by ¹⁸F-FDG but better lesion definition by ⁶⁸Ga-citrate for intracranial lesions. Our study also suggested that ⁶⁸Ga-citrate was less likely to accumulate in post-infective inflammation compared to ¹⁸F-FDG.


► **Tab. 6** Percentage change in mean target to liver SUVmax ratio of abnormal lesions in patient who had follow-up studies.

	Site of lesion	¹⁸ F-FDG	⁶⁸ Ga-citrate
Patient A	Lung and nodes	–33.6%	–47.5%
Patient B	Lung	–95.2%	–85%
Patient C	Nodes	–40.4%	–43.1%
Patient D	Nodes	–35.7%	–70.3%
Patient E	Brain, Lung	–70%	–63.4%

⁶⁸Ga-citrate, as a PET tracer, is particularly attractive to facilities that have no on-site cyclotron as the radionuclide, ⁶⁸Ga, is readily available in-house from good manufacturing practice (GMP) approved ⁶⁸Ga generators. The radiopharmaceutical is also easy to prepare, without the need for highly skilled radiopharmacist and technical staff needed to operate a cyclotron.

The management of TB can be challenging, especially in SNTB and EPTB, particularly in areas with a high prevalence of HIV. Imaging becomes very critical in the management of such cases. PET/CT has been found to be useful in the management of these complex TB cases [17]. The use of ⁶⁸Ga-citrate PET/CT to manage TB may be a particularly attractive prospect to developing economies with a high TB burden, where efforts are in place to increase the use of nuclear medicine [18].


Intracranial TB is associated with higher mortality rates than other forms of TB [19]. Objective assessment of therapy to guide clinicians in the management is essential [20]. The ability of PET to quantify disease burden using semi-quantitative indices makes it a particularly useful imaging technique for monitoring therapy. The application of ¹⁸F-FDG, the most commonly used PET tracer,



► **Fig. 2** Transverse PET, CT, and fused PET/CT images ^{18}F -FDG (left) and ^{68}Ga -citrate (right) of a patient with intracerebral TB with a better definition of the lesion on the ^{68}Ga -citrate image. The lesion can barely be visualized on the ^{18}F -FDG PET image only. The CT component of ^{18}F -FDG PET/CT was contrast enhanced.

is limited in intracerebral lesions because of significant physiologic brain uptake [17]. ^{68}Ga -citrate does not show physiologic tracer accumulation in the brain. Lesions in the brain can be detected with a high contrast resolution. Like ^{18}F -FDG, ^{68}Ga -citrate is a nonspecific tracer. ^{68}Ga -citrate does not only accumulate in TB but also in other conditions such as malignancy [21]. The role of ^{68}Ga -citrate in intracerebral lesions may not be limited to TB, but may also apply to other intracranial pathologies where ^{18}F -FDG has a poor clinical record in their management.

Our study suggests ^{68}Ga -citrate is less likely to accumulate in post-infective inflammation. This may become an important clinical application, especially since ^{18}F -FDG is known to persist in some TB lesions even after treatment [22]. More extensive studies will be required to investigate this role of ^{68}Ga -citrate further.



► **Fig. 3** a ^{18}F -FDG and b ^{68}Ga -citrate MIP images of the thighs and knees bilaterally of a 26-year-old male with microbiologically proven TB arthritis of the right knee. ^{18}F -FDG shows post-infective inflammation not taken up by ^{68}Ga -citrate in the lateral compartment of the right thigh (blue arrows) SUVmax 4.1. The patient had culture-confirmed staphylococcal abscesses two months before the ^{18}F -FDG PET/CT study that had been successfully treated with appropriate

The use of PET/CT in the evaluation of a co-infection of TB and HIV can be challenging. HIV-associated lymphadenopathy is known to be ^{18}F -FDG avid [23]. Treatment with antiretroviral and stage of HIV infection may influence the metabolic ^{18}F -FDG signal in the lymph nodes. Although ^{68}Ga -citrate is a non-specific tracer, there is currently no study to determine the uptake of ^{68}Ga -citrate in HIV-associated lymphadenopathy. Again, ^{68}Ga -citrate has not been as extensively studied in HIV-associated infection and malignancies as ^{18}F -FDG. In our study, we had over 70% of our patients with HIV. These patients had no clinical evidence of an alternative diagnosis such as HIV-associated malignancies at time of study and up to 2 years of follow up. The differences in the uptake and number of lesions detected by ^{18}F -FDG and ^{68}Ga -citrate are likely due to the differences in the mechanism of uptake and normal tracer biodistribution. The difference may also be related to differential uptake by the tracers in HIV-lymphadenopathy.

The findings from ^{18}F -FDG and ^{68}Ga -citrate would, in most cases (except for two), not have resulted in alteration of the treatment based on differences in PET/CT findings despite ^{18}F -FDG detecting more lesions. The standard treatment that is given to the patients with pulmonary TB or TB lymphadenitis susceptible to first-line therapy is six months on anti-TB drugs, so the additional lymph nodes detected by ^{18}F -FDG PET/CT would not have potentially altered the TB management. In two patients, however, the results of the PET/CT scans would have led to different management strategies. In the patient with pericarditis, the abnormal ^{18}F -FDG uptake in the pericardium (not visualized on ^{68}Ga -citrate) was considered to be TB pericarditis and led to a prolongation of anti-TB therapy to nine months instead of the standard six months used for pulmonary and nodal disease. In the patient who was assessed for residual TB spondylodiscitis, ^{18}F -FDG was unable to exclude residual TB convincingly, but lack of ^{68}Ga -citrate uptake suggested no residual disease; in this case, ^{68}Ga -citrate potentially led to the correct treat-

as it corresponded to the clinical strategy adopted by clinicians and was proven to be correct by clinical follow-up. Our study suggests ^{68}Ga -citrate PET/CT may detect the abnormal TB lesions detected by ^{18}F -FDG PET/CT however in special cases one tracer may have benefits over the other such as intracerebral lesions for ^{68}Ga -citrate PET/CT or pericarditis for ^{18}F -FDG PET/CT.

This is the first study comparing the role of ^{18}F -FDG and ^{68}Ga -citrate in TB patients. In a previous clinical study, the role of ^{68}Ga -citrate was compared to ^{18}F -FDG in patients with an infectious process, and the two were found to be comparable in the detection of staphylococcal osteomyelitis [24]. The authors found the SUV-max of soft tissue lesions with ^{68}Ga -citrate to be less than with ^{18}F -FDG, which is similar to our findings. The higher SUV of the ^{18}F -FDG lesions are due to the better physical properties of ^{18}F and led to a better definition of the abnormal lesions at most sites except in the brain. Despite this, our study showed that ^{68}Ga -citrate-PET/CT detected abnormal tracer uptake in all the patients who had TB. Another study evaluated the characteristics of ^{18}F -FDG and ^{68}Ga -citrate PET/CT in a condition characterized by a severe inflammatory process with necrosis due to the reaction to metal debris in patients with metal on metal hip arthroplasties [25]. ^{18}F -FDG PET/CT showed periprosthetic uptake in 94% (15/16) of hip arthroplasties with ^{68}Ga -citrate showing periprosthetic uptake in only 19% (3/16). The three hips that showed abnormal uptake on ^{68}Ga -citrate were the same hips that the pattern of uptake on ^{18}F -FDG PET/CT was suggestive of an infection, although infection was confirmed in only one hip. These findings are consistent with our finding that ^{68}Ga -citrate is less likely to accumulate in inflammatory lesions with no active infection compared to ^{18}F -FDG. Again, a more recent study found ^{68}Ga -citrate was more specific than ^{18}F -FDG in distinguishing infected lower limb prosthesis from sterile inflammation [26]. This critical role must be explored further due to the limited number of post-infective lesions we had in our study.

Our study has some limitations. It has a small sample size, the differences in anti-TB treatment duration, time between ^{18}F -FDG and ^{68}Ga -citrate studies. Again, although all patients had sufficient clinical data for follow-up as per international and national algorithms, histology could not be done on all patients as biopsy was not always possible. The activity injected for ^{68}Ga -citrate has not yet been standardized.

The duration between the ^{18}F -FDG and ^{68}Ga -citrate was variable but less than 12 days with more than 85% (20 out of the 23) done by six days (► **Table 3**). *Mycobacterium tuberculosis* is a relatively slow-growing organism with the treatment of active disease lasting at least six months. The duration of fewer than two weeks between the ^{18}F -FDG and ^{68}Ga -citrate is unlikely to change the tracer uptake significantly.

Large prospective studies evaluating the role of a more homogenous population such as patients with suspected residual disease TB spondylodiscitis or intracerebral TB will be needed to fully exploit the potential advantages offered by ^{68}Ga -citrate PET/CT in the management of TB. The role of ^{68}Ga -citrate in non-TB bacterial infection and other granulomatous processes with high ^{18}F -FDG uptake must be investigated further.

CONCLUSION

Our preliminary data shows that ^{18}F -FDG detects more abnormal lesions than ^{68}Ga -citrate in patients being managed for tuberculosis. However, ^{68}Ga -citrate has better lesion definition of intracranial lesions and may be especially indicated for such lesions. The study provides data and a basis for large multicenter prospective studies of the use of ^{68}Ga -citrate in TB.

Disclosure

The authors report no conflict of interest relevant to this article.

Acknowledgments

The authors wish to acknowledge all the staff of the Nuclear Medicine department of the Steve Biko Academic Hospital and patients who consented to be part of the study

Conflict of interest ■ Please check, add if necessary

The authors declare there is no conflict of interest.

References

- [1] Global tuberculosis report 2018. Geneva: World Health Organization; 2018. Im Internet: <http://apps.who.int/iris/bitstream/handle/10665/274453/9789241565646-eng.pdf>; Assessed January 18, 2019
- [2] Improving the diagnosis and treatment for smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents. Recommendations for HIV-prevalent and resource-constrained settings. WHO 2007. Im Internet: http://apps.who.int/iris/bitstream/handle/10665/69463/WHO_HTM_TB_2007.379_eng.pdf;jsessionid=244682331B1F968F813FD965BF270051?sequence=1; Assessed January 18, 2019
- [3] Wilson D, Mbhele L, Badri M et al. Evaluation of the World Health Organization algorithm for the diagnosis of HIV-associated sputum smear-negative tuberculosis. *Int J Tuberc Lung Dis* 2011; 15: 919–924
- [4] Department of Health, Republic of South Africa. National Tuberculosis Management Guidelines, Department of Health, South Africa 2014. Im Internet: http://www.tbonline.info/media/uploads/documents/ntcp_adult_tb-guidelines-27.5.2014.pdf; Assessed 18 January 2019
- [5] Walley J, Kunutsor S, Evans M et al. Validation in Uganda of the new WHO diagnostic algorithm for smear-negative pulmonary tuberculosis in HIV prevalent settings. *J Acquir Immune Defic Syndr* 2011; 57: e93–e100
- [6] Linguissi LS, Vouvongui CJ, Poulain P et al. Diagnosis of smear-negative pulmonary tuberculosis based on clinical signs in the Republic of Congo. *BMC Res Notes* 2015; 8: 804
- [7] The Stop TB Strategy. WHO. Im Internet: www.who.int/tb/strategy/stop_tb_strategy/en/; Accessed August 4, 2018

- [8] Sathekge M, Maes A, Van de Wiele C. FDG-PET imaging in HIV infection and tuberculosis. *Semin Nucl Med* 2013; 43: 349–366
- [9] Ankrah AO, van der Werf TS, de Vries EF et al. PET/CT imaging of *Mycobacterium tuberculosis* infection. *Clin Transl Imaging* 2016; 4: 131–144
- [10] Banerjee SR, Pomper MG. Clinical Applications of Gallium-68. *Appl Radiat Isot* 2013; 0: 2–13
- [11] Vorster M, Maes A, Wiele Cv et al. Gallium-68 PET: A Powerful Generator-based Alternative to Infection and Inflammation Imaging. *Semin Nucl Med* 2016; 46: 436–447
- [12] Nanni C, Errani C, Boriani L et al. ⁶⁸Ga-citrate PET/CT for evaluating patients with infections of the bone: preliminary results. *J Nucl Med* 2010; 51: 1932–1936
- [13] Kumar V, Boddeti DK, Evans SG et al. (⁶⁸Ga-Citrate-PET for diagnostic imaging of infection in rats and for intra-abdominal infection in a patient. *Curr Radiopharm* 2012; 5: 71–75
- [14] Vorster M, Maes A, Van de Wiele C et al. ⁶⁸Ga-citrate PET/CT in Tuberculosis: A pilot study. *Q J Nucl Med Mol Imaging* 2019; 63: 48–55
- [15] Vorster M, Mokaleng B, Sathekge MM et al. A modified technique for efficient radiolabeling of ⁶⁸Ga-citrate from a SnO₂-based ⁶⁸Ge/⁶⁸Ga generator for better infection imaging. *Hell J Nucl Med* 2013; 16: 193–198
- [16] Rizzello A, Di Piero D, Lodi F et al. Synthesis and quality control of ⁶⁸Ga citrate for routine clinical PET. *Nucl Med Commun* 2009; 30: 542–545
- [17] Ankrah AO, Glaudemans AWJM, Maes A et al. Tuberculosis. *Semin Nucl Med*. 2018; 48: 108–130
- [18] Dondi M, Kashyap R, Paez D et al. Trends in nuclear medicine in developing countries. *J Nucl Med* 2011; 52: 16S–23S
- [19] El Sahly HM, Teeter LD, Pan X et al. Mortality Associated with Central Nervous System Tuberculosis. *The Journal of infection*. 2007; 55: 502–509
- [20] Torres C, Riascos R, Figueroa R et al. Central nervous system tuberculosis. *Top Magn Reson Imaging*. 2014; 23: 173–189
- [21] Malherbe ST, Shenai S, Ronacher K et al. Persisting positron emission tomography lesion activity and *Mycobacterium tuberculosis* mRNA after tuberculosis cure. *Nat Med* 2016; 22: 1094–1100
- [22] Vorster M, Maes A, Jacobs A et al. Evaluating the possible role of ⁶⁸Ga-citrate PET/CT in the characterization of indeterminate lung lesions. *Ann Nucl Med* 2014; 28: 523–530
- [23] Lucignani G, Orunesu E, Cesari M et al. FDG-PET imaging in HIV-infected subjects: relation with therapy and immunovirological variables. *Eur J Nucl Med Mol Imaging* 2009; 36: 640–647
- [24] Salomäki SP, Kempainen J, Hohenthal U et al. Head-to-Head Comparison of ⁶⁸Ga-Citrate and ¹⁸F-FDG PET/CT for Detection of Infectious Foci in Patients with *Staphylococcus aureus* Bacteraemia. *Contrast Media Mol Imaging* 2017; 2017: 3179607
- [25] Aro E, Seppänen M, Mäkelä KT et al. PET/CT to detect adverse reactions to metal debris in patients with metal-on-metal hip arthroplasty: an exploratory prospective study. *Clin Physiol Funct Imaging* 2018; 38: 847–855
- [26] Tseng JR, Chang YH, Yang LY et al. Potential usefulness of ⁶⁸Ga-citrate PET/CT in detecting infected lower limb prostheses. *EJNMMI Res*. 2019; 9: 2